The present invention provides compounds of formula (I), and pharmaceutical compositions thereof. ##STR00001##

The invention provides compounds of formula (I):

##STR00001##

wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.

The invention provides compounds of formula (I):

##STR00001##

wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.

In its many embodiments, the present invention provides certain substituted bispiperidinyl compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, L, R.sup.4, Q and R.sup.5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X- receptor (LXR) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

##STR00001##

A method is disclosed for synthesizing a zeolite having the framework structure of SSZ-16 using a structure directing agent comprising a dication selected from one or more of 1,1-(1,4-cyclohexylenedimethylene)bis[1-methylpiperidinium]; 1,1-(1,4-cyclohexylenedimethylene)bis[1-ethylpiperidinium]; 1,1-(1,4-cyclohexylenedimethylene)bis[1-methylpyrrolidinium]; and 1,1-(1,4-cyclohexylenedimethylene)bis[1-ethylpyrrolidinium].

This invention provides for a compound of formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein R.sup.1-R.sup.4, L.sub.1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

This invention provides for a compound of formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein R.sup.1-R.sup.4, L.sub.1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

The present invention provides compounds of formula (I), and pharmaceutical compositions thereof. ##STR00001##

The present invention provides compounds of formula (I), and pharmaceutical compositions thereof. ##STR00001##

The present invention provides compounds of formula (I), and pharmaceutical compositions thereof. ##STR00001##